- Home
- EXP vs VRNA Comparison
EXP vs VRNA Comparison
Compare EXP & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXP
- VRNA
- Stock Information
- Founded
- EXP 1963
- VRNA 2005
- Country
- EXP United States
- VRNA United Kingdom
- Employees
- EXP N/A
- VRNA N/A
- Industry
- EXP Building Materials
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- EXP Industrials
- VRNA Health Care
- Exchange
- EXP Nasdaq
- VRNA Nasdaq
- Market Cap
- EXP 7.2B
- VRNA 8.3B
- IPO Year
- EXP 1994
- VRNA 2017
- Fundamental
- Price
- EXP $233.29
- VRNA $106.43
- Analyst Decision
- EXP Buy
- VRNA Buy
- Analyst Count
- EXP 9
- VRNA 11
- Target Price
- EXP $263.11
- VRNA $114.10
- AVG Volume (30 Days)
- EXP 304.4K
- VRNA 1.3M
- Earning Date
- EXP 10-28-2025
- VRNA 11-03-2025
- Dividend Yield
- EXP 0.43%
- VRNA N/A
- EPS Growth
- EXP N/A
- VRNA N/A
- EPS
- EXP 13.58
- VRNA N/A
- Revenue
- EXP $2,286,509,000.00
- VRNA $221,673,000.00
- Revenue This Year
- EXP $3.61
- VRNA $896.59
- Revenue Next Year
- EXP $4.65
- VRNA $77.56
- P/E Ratio
- EXP $17.18
- VRNA N/A
- Revenue Growth
- EXP 0.88
- VRNA N/A
- 52 Week Low
- EXP $191.91
- VRNA $27.54
- 52 Week High
- EXP $321.93
- VRNA $106.45
- Technical
- Relative Strength Index (RSI)
- EXP 52.19
- VRNA 73.36
- Support Level
- EXP $227.09
- VRNA $106.15
- Resistance Level
- EXP $238.20
- VRNA $106.42
- Average True Range (ATR)
- EXP 5.59
- VRNA 0.20
- MACD
- EXP -0.35
- VRNA -0.16
- Stochastic Oscillator
- EXP 54.90
- VRNA 97.90
About EXP Eagle Materials Inc
Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.